tbuckley/cabot-search huggingface dataset:
CMET-02. NON-ENHANCING METASTATIC DISEASE OF THE CNS, A CASE REPORT
Authors: Luke Bramlage, Anna Pollack, Larry Hall, Benjamin McCalip
Journal: Neuro-Oncology (2017)

Lung and breast cancer are the two most likely neoplasms to metastasize to the brain. To visualize metastatic disease, MRI is the most sensitive imaging modality and commonly shows enhancing lesions. This is a first report of two different cases of metastatic disease presenting with non-enhancing lesions. The first case is a 62 year old female who presented with a history of breast cancer and two non-enhancing cerebellar lesions. These lesions were surgically drained for symptomatic relief and on frozen pathology, breast adenocarcinoma was found. Upon cytology, the lesion was found to be metastatic ER+, PR+, and HER-2- breast adenocarcinoma which is not as likely to metastasize. Two years post-op, the patient has been doing well with resolution of symptoms and is currently tolerating treatment. The second case is a 70 year old male with lung cancer who presented with several non-enhancing lesions upon imaging. No histology was performed on these lesions but in follow-up imaging, they decreased in size after immunotherapy. These case reports are important to give an example of a patients who presents with non-enhancing lesions that were in fact metastatic disease.
Association Between Adolescent Preventive Care and the Role of the Affordable Care Act
Authors: Sally H. Adams, M. Jane Park, Lauren Twietmeyer, Claire D. Brindis, Charles E. Irwin
Journal: JAMA Pediatrics (2017)

Despite decades of adolescent preventive well visit and services promotion (Guidelines for Adolescent Preventive Services and Bright Futures), rates are below recommended levels and little is known of the effect of the Patient Protection and Affordable Care Act (ACA) implementation on these care rates.To use Medical Expenditure Panel Survey data to determine (1) whether adolescent well visit rates increased from the pre-ACA period to post-ACA period, and (2) whether caregivers' reports of past-year preventive services delivery increased from the pre- to post-ACA period among adolescents with any past-year health care visit.Secondary data analysis of 2007-2009 (before ACA implementation) and 2012-2014 (after ACA implementation) Medical Expenditure Panel Survey data on the differences in well visits and preventive services. Data were collected through computer-assisted personal interviews of caregivers of a nationally representative sample of a noninstitutionalized US population (n = 25 695 10- to 17-year-old adolescents).For objective 1, pre- to post-ACA period differences in past-year well visits: (1) stratified bivariable logistic regressions identifying subgroup rate differences and (2) multivariable analyses controlling for demographic factors. For objective 2, pre- to post-ACA period differences in caregiver reports of preventive services receipt, including time alone with clinician: (1) bivariable (year differences) and (2) multivariable logistic regressions controlling for demographic variables.A total of 6279 (50.9%) and 6730 (50.8%) participating adolescents in the pre- and post-ACA period data were male, respectively. Under objective 1, we found that well-visit rates increased from 41% to 48% post-ACA implementation (odds ratio, 1.3; 95% CI, 1.2-1.5); minority and low-income groups had the greatest increases. Under objective 2, we found that among those with any past-year visit, most preventive services rates (8 of 9) increased post-ACA implementation (range, 2%-9%, absolute), with little or no change when controlling for demographic variables. Time alone with clinicians increased 1%, significant only when covariates were controlled (adjusted odds ratio, 1.2; 95% CI, 1.0-1.3).Despite modest to moderate increases, with greatest gains for underserved youth, adolescent preventive care rates remain low, highlighting the need for increased efforts to bring adolescents into well care and improve clinician delivery of preventive care within their practices.
La legionelosis en Europa en 2003-2004
Authors: K D Ricketts, C Joseph
Journal: Eurosurveillance (2005)

Una vez al ano los paises colaboradores del Grupo de trabajo europeo para la vigilancia de la legionelosis asociada a viajes (EWGLINET) deben proporcionar una serie de datos con informacion epidemiologica y microbiologica de los casos de legionelosis (infecciones nosocomiales, comunitarias o asociadas a viajes) detectados en su pais durante dicho ano. El siguiente articulo presenta los datos correspondientes a 2003 y 2004. Durante este periodo, fueron declarados 9.166 casos por 35 paises, de los cuales 941 casos estuvieron ligados a brotes. Catorce paises declararon un total de 218 brotes. La tasa de infeccion variaba de un pais a otro, desde 28,7% a menos de un caso por millon de habitantes. Esta informacion es importante puesto que permite que los paises evaluen la eficacia de sus programas de vigilancia para la deteccion de casos. 
Durante los dos anos estudiados, se declararon 748 defunciones, lo que representa una tasa de mortalidad del 8,2%. Hay que resaltar la falta de informacion epidemiologica detallada sobre las defunciones debidas a la legionelosis. La creacion del Centro europeo para el control y la prevencion de las enfermedades es una oportunidad para reforzar la colaboracion y mejorar la proteccion de los europeos frente a brotes de legionelosis.
Incidence du génotype Beijing de Mycobacterium tuberculosis à Elche (Espagne): étude de surveillance sur 13 ans
Authors: E Garcia-Pachon, I Escribano, J C Rodriguez, M Ruiz, J M Ramos, J F Navarro, G Royo
Journal: Eurosurveillance (2007)

Des souches du genotype Beijing de Mycobacterium tuberculosis ont ete associees a des epidemies et a une multiresistance aux medicaments. Nous avons mene une etude de surveillance retrospective sur 13 ans (1993 – 2005) pour en savoir plus sur l’occurrence de cette souche a Elche, en Espagne.
NIMG-98. ASSESSMENT OF TUMOR HYPOXIA AND PERFUSION IN GBM FOLLOWING BEV FAILURE USING FMISO 18F-PET AND MRI
Authors: Shiliang Huang, Yichu Liu, David Reardon, Patrick Y Wen, Peter Fox, Mark Muzi, Eudocia Lee, Andrew Brenner
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM, WHO grade IV) is the most common and aggressive of the primary brain tumors in adults. As part of an ongoing clinical trial with a hypoxia activated prodrug, we sought to explore the correlation between abnormal tumor vasculature and hypoxia in GBM following bevacizumab (BEV) failure. MRI and 18F-FMISO PET scans were acquired at study entry. Associations between baseline hypoxia volume (HV), SUV peak, as measured by FMISO PET and vascular parameters including rCBV, TTP, enhancing and non-enhancing tumor volumes as measured by dynamic susceptibility contrast imaging (DSC), T1 post contrast and FLAIR was determined using Pearson correlation. Each marker was modeled with a univariate cox regression model for progression free survival (PFS) time. 8 patients from University of Texas Health Science center and 14 patients from Dana-Farber Cancer Institute had evaluable MR and PET imaging. Significant positive correlations were found between HV and enhancing volume (R=0.6884, p<0.0001) as well as volume ratio and srCBV (R=0.6032, p<0.0001). Moderate positive correlation were found between volume ratio and HV (R=0.5049, p=0.0165) as well as volume ratio and SUVpeak (R=0.5669, p=0.0059). Nonenhancing volume is associated with HV (R=0.2602, p=0.0153) so is SUVpeak and srCBV (R=0.3253, p=0.0056). In the univariate cox model, bigger enhancing (p=0.043), nonenhancing (p=0.0061) and HV (p=0.0172) were significantly associated with shorter progression time. The hypoxic volume following bevacizumab failure correlates with both the volume of enhancement and the fraction of enhancement within the mass. Findings from the full 23 patient cohorts and the association with other biomarkers and response to treatment is being assessed and will be presented.
P1.01-075 Simultaneous Multiplex Profiling of Gene Fusions, METe14 Mutations and Immune Genes in Advanced NSCLC by NCounter Technology
Authors: N. Reguart, C. Teixidó, A. Giménez-Capitán, N. Vilariño, A. Arcocha, P. Jares, S. Castillo, X. Bernal, S. Muñoz, R. Palmero, I. Sullivan, M. Marginet, N. Viñolas, D. Martinez, N. Baixeras, M. Molina-Vila, A. Prat
Journal: Journal of Thoracic Oncology (2017)
Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy
Authors: Francesca Branzoli, Anna Luisa Di Stefano, Laurent Capelle, Chris Ottolenghi, Romain Valabrègue, Dinesh K Deelchand, Franck Bielle, Chiara Villa, Bertrand Baussart, Stéphane Lehéricy, Marc Sanson, Małgorzata Marjańska
Journal: Neuro-Oncology (2017)

Mutations in the isocitrate dehydrogenase (IDH) enzyme affect 40% of gliomas and represent a major diagnostic and prognostic marker. The goals of this study were to evaluate the performance of noninvasive magnetic resonance spectroscopy (MRS) methods to determine the IDH status of patients with brain gliomas through detection of the oncometabolite 2-hydroxyglutarate (2HG) and to compare performance of these methods with DNA sequencing and tissue 2HG analysis.Twenty-four subjects with suspected diagnosis of low-grade glioma were included prospectively in the study. For all subjects, MRS data were acquired at 3T using 2 MRS methods, edited MRS using Mescher-Garwood point-resolved spectroscopy (MEGA-PRESS) sequence and a PRESS sequence optimized for 2HG detection, using a volume of interest larger than 6 mL. IDH mutational status was determined by a combination of automated immunohistochemical analysis and Sanger sequencing. Levels of 2HG in tissue samples measured by gas chromatography-mass spectrometry were compared with those estimated by MRS.Edited MRS provided 100% specificity and 100% sensitivity in the detection of 2HG. The 2HG levels estimated by this technique were in line with those derived from tissue samples. Optimized PRESS provided lower performance, in agreement with previous findings.Our results suggest that edited MRS is one of the most reliable tools to predict IDH mutation noninvasively, showing high sensitivity and specificity for 2HG detection. Integrating edited MRS in clinical practice may be highly beneficial for noninvasive diagnosis of glioma, prognostic assessment, and treatment planning.
Hypertonic Saline and Acute Bronchiolitis
Authors: Xavier Tanguay-Rioux, Anali Maneshi, Hajar Al Hoqani
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Family history of pancreatic cancer in BRCA1/2 testing criteria
Authors: A. Toss, M. Venturelli, S. Pipitone, I. Marchi, E. Tenedini, V. Medici, E. Tagliafico, E. Razzaboni, F. Spaggiari, E. De Matteis, S. Cascinu, L. Cortesi
Journal: Annals of Oncology (2017)
Epidemiología de la rubéola en Finlandia
Authors: I Davidkin, H Peltola, P Leinikki
Journal: Eurosurveillance (2004)

Antes de ponerse en marcha los programas de vacunacion contra la rubeola, la infeccion por rubeola era prevalente en los ninos finlandeses. La enfermedad aparecia a intervalos de varios anos en forma de epidemia. Los ninos de 2 a 12 anos eran los que contraian la infeccion por rubeola con mayor frecuencia. A mediados de los anos setenta, con la vacuna monovalente comenzaron las vacunaciones destinadas especificamente a erradicar la rubeola, y en 1982 dio comienzo el programa de vacunacion con la triple virica (MMR). Pocos anos despues del inicio del programa MMR se pudo apreciar una clara reduccion de casos de rubeola. Gracias a la cobertura vacunal suficientemente alta (g95% desde 1987), a finales de los anos noventa dejo de circular en la poblacion finlandesa el virus de la rubeola indigeno. Desde su eliminacion, se han importado algunos casos de rubeola en Finlandia pero no han dado lugar a casos secundarios. Esto demuestra sin lugar a dudas que la proteccion contra la rubeola mantiene su eficacia, pese a que nuestros estudios de cohorte dan a entender que los niveles de anticuerpos inducidos por la vacuna disminuyen con el tiempo. El programa MMR tambien elimino el sindrome de rubeola congenita (SRC) en el pais. El ultimo caso de SRC se registro en 1986. Como consecuencia del programa de vacunacion con MMR de elevada cobertura, la rubeola quedo definitivamente erradicada de Finlandia. Aun es pronto para determinar la duracion de la proteccion adquirida.
P2.01-013 Nab-Paclitaxel/Carboplatin in Elderly Patients with NSCLC (ABOUND.70+): Analysis of Safety and Quality of Life (QoL) by Cycle
Authors: E. Kim, J. Weiss, E. Anderson, R. Jotte, J.W. Goldman, D. Haggstrom, D. Smith, C. Dakhil, K. Konduri, T. Berry, T.J. Ong, A. Sanford, K. Amiri, C. Langer
Journal: Journal of Thoracic Oncology (2017)
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC)
Authors: L. Carbognin, I. Sperduti, G. Arpino, M.V. Dieci, F. Schettini, V. Guarneri, G. Griguolo, R. Nortilli, E. Fiorio, V. Parolin, S. Pilotto, M. Brunelli, E. Manfrin, E. Orvieto, F. Pellini, G.P. Pollini, P. Conte, S. De Placido, G. Tortora, E. Bria
Journal: Annals of Oncology (2017)
P2.03-017 Clinical Features and Treatment with Afatinib in Patients with Squamous Cell Lung Cancer with Sensitive EGFR Mutations
Authors: Y. Taniguchi, A. Saihara, Y. Matsumoto, R. Furukawa, S. Ohara, A. Sato, M. Hojou, K. Usui
Journal: Journal of Thoracic Oncology (2017)
SCDT-06. QUANTIFIABLE LEVELS OF THE TRANSGENE, CYTOSINE DEAMINASE, IN TUMOR SAMPLES FOLLOWING INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
Authors: Tobias Walbert, Danilella Bota, Michael Vogelbaum, Steven Kalkanis, Linda Liau, Tom Mikkelsen, Harry Gruber, Jolene Shorr, Maria Rodriguez-Aguirre, Derek Ostertag, Leah Mitchell, Doug Jolly, Timothy Cloughesy
Journal: Neuro-Oncology (2017)

Toca 511 (vocimagene amiretroprepvec) is an investigational, conditionally lytic, retroviral replicating vector that encodes an optimized yeast cytosine deaminase (CD) gene. The CD gene converts the prodrug, Toca FC (investigational, extended-release 5-fluorocytosine), into the chemotherapeutic, 5-FU in infected tumors. In a Phase 1 study (NCT01985256), Toca 511 was injected intravenously for 1, 3, or 5 days to patients with recurrent high grade glioma. Tumors were subsequently resected, and Toca 511 was injected into the resection cavity walls. At the time of resection, tissue from various regions of the tumor was collected and processed for quantitative PCR analysis of CD RNA and DNA. Tissue from corresponding locations was fixed for assessment of CD protein expression by immunohistochemistry (IHC). Expression of CD protein was quantified based on immunofluorescence signal and was shown to co-localize in cells with detectable levels of gag, a viral structural protein. CD protein expression by IHC was assessed in tissue from locations that corresponded with samples positive for CD by PCR and ranged from 1.16% to 10.4% area of the field. These data show that intravenous delivery of Toca 511 results in appreciable deposition of vector in the tumor. Further, we have observed an inverse correlation between T cell infiltrate in the tumor microenvironment and clinical benefit in a complementary Phase I study in which Toca 511 was solely delivered into the resection cavity. Therefore, the nature of the study design described herein, which uses IV delivery of Toca 511, provides a unique opportunity to assess the spatial relationship between CD protein expression and histological features of the tumor. Immunohistochemical assessment to determine spatial correlates between CD protein and T cells, T regulatory cells, and immunosuppressive myeloid cells will be presented. Updated clinical response data will also be presented.
P2.13-022 Lung Nodule Survey: One Pathology, Perspectives from Thoracic Surgeon, Pulmonologist and Radiology Point of View
Authors: M.T. Ruiz Tsukazan, R. Terra, I. Santoro, G. Fortunato, G. Meirelles, F. Detterbeck
Journal: Journal of Thoracic Oncology (2017)
Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels
Authors: B. Ricciuti, R. Chiari, F.R. Tofanetti, A. De Giglio, R. Porreca, M. Brambilla, I. Sperduti, G. Bellezza, C. Mencaroni, A. Siggillino, D. Zicari, A. Baldi, V. Ludovini, G. Metro
Journal: Annals of Oncology (2017)
STEM-31. TARGETING GLIOBLASTOMA STEM CELLS BY PERTURBING A NOVEL GENE REGULATORY CLUSTER TO REDUCE TUMOR RECURRENCE
Authors: Changwang Deng, Mathew Sebastian, Son Le, Dongjiang Chen, Nagheme Thomas, David Tran
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) is the most prevalent and aggressive brain cancer in adults. GBM is enriched with glioma stem-like cells (GSCs) that contribute to tumor initiation and treatment resistance and thus a natural focus for therapeutic development. However, targeting GSCs has been a challenge because of the dearth of knowledge of master regulators specific to GSCs and not to normal brain cells. Therefore systematic elucidation of the GSC-specific core regulatory program will improve our understanding of GSC biology and provide an opportunity to develop novel GSC-specific therapy with maximal efficacy and minimal toxicity. To accomplish these objectives, we have recently developed two innovative computational platforms, GeneRep and nSCORE and experimentally validated them in several published datasets. The tandem platforms complement each other and allow us to 1) interrogate large-scale gene expression profiles of GSCs, GBM-differentiated cells, normal neuronal precursor cells (NPCs) and astrocytes (NAs) to extract candidate GSC-specific gene regulatory networks, and 2) functionally rank GSC-specific core master regulators, respectively. A cluster of 8 interrelated master subnetworks emerged, which were functionally grouped into the stemness and cancer pathways, some of which belonging to the Sox, Olig and Myc families. By enforcing the-expression of this cluster in NAs, we were able to reprogram these normal cells into GSCs as measured by the neurosphere formation and in vivo tumorigenesis assays, confirming the critical requirement of this cluster for the GSC identity. Furthermore this network cluster was present and functioned cooperatively to maintain GSCs in several patient-derived GSC lines examined to date. Survival and neurosphere formation rates of GSCs were profoundly suppressed when at least two nodes in this cluster were knock down by siRNA compared to depletion of individual nodes. Our data establish a novel gene regulatory cluster controlling GSCs and provide a compelling rationale for its therapeutic targeting to reduce tumor recurrence.
GP appointments last less than five minutes for half the world’s population
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Primary care consultations last less than five minutes for half of the world’s population, a large international analysis has found.

The research,1 published in BMJ Open , reveals wide variation in the average consultation length across the globe, with examples ranging from just 48 seconds in Bangladesh to 22.5 minutes in Sweden.

Researchers from a range of academic institutions reviewed the data on consultation length from 178 relevant studies covering 67 countries and more than 28.5 million consultations.

The analysis included peer reviewed research and “grey literature”—defined as research …
CSIG-27. PATIENT-DERIVED CELL ORIGINATED SECRETOME ANALYSIS IDENTIFIES MIDKINE AS A POTENT THERAPEUTIC TARGET IN GLIOBLASTOMA
Authors: Hyemi Shin, Jason Sa, Do-Hyun Nam
Journal: Neuro-Oncology (2017)

Glioblastoma multiforme (GBM) is the most malignant form of central nervous system tumor. Growth factors that are included as a supplement in a conditioned media is essential for culturing GBM cells. We discovered a subset of patient-derived cells that exhibit high cellular proliferation in the absence of supplemental growth factors. In order to identify autocrine growth factors that govern tumor cell growth, we utilized proteomics analysis from the growth-factor free conditioned media from two GBM cells and identified Midkine (MDK) as one of the prominent cytokines during GBM proliferation. Midkine is a major secretome in excess of 300 proteins. We inhibited tumor cells using recombinant lentiviral vector of MDK or neutralizing antibody. After MDK expression level was suppressed in vitro, cell cycle and cell proliferation rate were significantly down-regulated as well. Furthermore, pathway analysis has revealed specific pathways that are associated with reactive oxygen species stress were up-regulated.
QLIF-41. UNDERSTANDING EMOTIONAL DISTRESS IN PRIMARY BRAIN TUMOR PATIENTS: IS THERE A RELATIONSHIP WITH FEAR OF DEATH?
Authors: Ashlee Loughan, Sarah Braun
Journal: Neuro-Oncology (2017)

Learning of a terminal diagnosis may lead to emotional distress including symptoms of depression and anxiety. In fact, depression prevalence rates are as high as 40% in brain tumor patients. Although quality of life has received increased interest in cancer populations, little is known about brain tumor patients’ underlying fear of death and its potential relationship to overall emotional distress. Fifty-one patients (51% male, Mage 49yrs, Medu 15yrs) diagnosed with primary brain tumors participated in routine neuropsychological evaluations including emotional questionnaires: Beck Anxiety Inventory (BAI) and Beck Depression Inventory 2nd edition (BDI-II). A single-item question from the BAI assessed fear of dying. Descriptive analyses, t-tests, and Pearson correlations were conducted to explore the relationship between patients’ fear of dying and overall symptoms of depression and anxiety. For analyses of overall anxiety symptoms, the single-item question assessing fear of dying was removed to reduce multicollinearity. Thirty-five percent (n =18) of patients reported fear of dying at the time of evaluation. Anxiety scores (BAI) were significantly higher for patients who reported a fear of dying (M =16.56, SD =11.258) when compared to those who did not (M =9.00, SD =8.895); t(49) = -2.637, p = .011. There was also a positive correlation between the severity of fear and overall depression (BDI-II; r =.294, p =.036) and anxiety scores (BAI; r =.549, p =.000). All descriptive statistics and relationships between variables will be presented. Fear of dying was high in this sample of brain tumor patients. Patients who reported this fear had higher levels of anxiety and depression than those who did not. This was demonstrated between groups and when exploring fear severity levels. This research provides insight into the distress experienced by brain tumor patients, which may lead to more effective emotional interventions and improved quality of life.